ADARx Pharmaceuticals is a company developing an RNA-targeting platform for creating therapeutics. It offers an oligonucleotide targeting solution for inhibition, degradation, and editing, as well as oligonucleotide delivery technologies. The company focuses on developing treatments for genetic, cardiometabolic, and central nervous system diseases.